Akebia Ther Stock Investor Sentiment

AKBA Stock  USD 1.98  0.06  2.94%   
About 66% of Akebia Ther's investor base is looking to short. The analysis of the overall investor sentiment regarding Akebia Ther suggests that many traders are alarmed. The current market sentiment, together with Akebia Ther's historical and current headlines, can help investors time the market. In addition, many technical investors use Akebia Ther stock news signals to limit their universe of possible portfolio assets.
  

Akebia Ther Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Akebia Ther can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a month ago at investing.com         
Akebia Ther earnings missed by 0.04, revenue fell short of estimates
Investing News at Macroaxis
over a month ago at seekingalpha.com         
Akebia GAAP EPS of -0.10, revenue of 37.4M
seekingalpha News
over a month ago at finance.yahoo.com         
Akebia Therapeutics Q3 Earnings Snapshot
Yahoo News
over a month ago at finance.yahoo.com         
Akebia Therapeutics Reports Q3 Loss, Misses Revenue Estimates
Yahoo News
over a month ago at seekingalpha.com         
Akebia Q3 2024 Earnings Preview
seekingalpha News
over a month ago at www.macroaxis.com         
Acquisition by Rogers Michael W of 30000 shares of Akebia Ther subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over a month ago at finance.yahoo.com         
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highl...
Yahoo News
over a month ago at simplywall.st         
Akebia Therapeutics shareholder returns have been respectable, earning 91 percent in 1 year
Simply Wall St News at Macroaxis
over a month ago at thelincolnianonline.com         
Akebia Therapeutics Given Buy Rating at HC Wainwright
news
over a month ago at seekingalpha.com         
Akebia stock climbs 8 percent on dialysis provider supply agreement
seekingalpha News
over a month ago at finance.yahoo.com         
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Ac...
Yahoo News
over a month ago at finance.yahoo.com         
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
Yahoo News
over two months ago at finance.yahoo.com         
CMS Grants TDAPA Reimbursement for Vafseo beginning January 1, 2025
Yahoo News
over two months ago at seekingalpha.com         
Akebia gains additional CMS reimbursement for end-stage renal disease drug Vafseo
seekingalpha News
Far too much social signal, news, headlines, and media speculation about Akebia Ther that are available to investors today. That information is available publicly through Akebia media outlets and privately through word of mouth or via Akebia internal channels. However, regardless of the origin, that massive amount of Akebia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akebia Ther news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akebia Ther relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akebia Ther's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akebia Ther alpha.

Akebia Ther Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
10/15/2024
2
Akebia Therapeutics Given Buy Rating at HC Wainwright
10/23/2024
3
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
11/01/2024
4
Acquisition by Rogers Michael W of 30000 shares of Akebia Ther subject to Rule 16b-3
11/05/2024
5
Akebia Ther earnings missed by 0.04, revenue fell short of estimates
11/07/2024
6
Earnings call Akebia reports Q3 results, gears up for Vafseo launch
11/08/2024
7
Akebia Therapeutics Downgraded to Sell Rating by StockNews.com
11/22/2024
8
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
12/03/2024
9
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - The Eastern Progress Online
12/06/2024

Complementary Tools for Akebia Stock analysis

When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Commodity Directory
Find actively traded commodities issued by global exchanges